Unlocking the Value of Biosimilars: Challenges and Solutions

By Danélia Botes

August 10, 2023

The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) has recently published a report highlighting the gaps and challenges in the value assessment of biosimilars.

The report brings to light the ongoing debate on how to accurately assess the value of biosimilars, especially when they request reimbursement for the same indication as the reference biologic. The report also touches upon the different regulatory requirements for biosimilars across various jurisdictions.

The aim of this review is to provide an overview of the existing challenges and propose potential approaches to address them. This could pave the way for improved methodologies in economic evaluation and better access to these therapies in different jurisdictions.

Assessing the value of a biosimilar, a biological product highly similar to an already approved biological product, can be done through either a price comparison or a full economic evaluation. The choice of method depends on factors such as the relative efficacy of the reference biologic and the biosimilar, indication extrapolation, and value assessment in biologic-naive and biologic-experienced patients. A price comparison is typically used when the two products differ significantly in terms of costs, but not effectiveness. However, a full economic evaluation is required when the reference biologic is not reimbursed, has not been appraised, or is not the standard of care. Some countries, such as Belgium, France, and the Netherlands, classify biosimilars as products with no added therapeutic value compared to the reference biologic. Therefore, they have implemented an abbreviated pricing and reimbursement pathway for biosimilars. The value assessment of a biosimilar is a dynamic process and may need to be revisited as new evidence emerges.

The ISPOR Special Interest Group on Biosimilars is committed to generating new insights in this field by interviewing experts at Health Technology Assessment (HTA) agencies worldwide.

For the full report follow the link below.

Reference url

Recent Posts

Cutaneous Malignant Melanoma Treatment

Forecasting Innovations in Cutaneous Malignant Melanoma Treatment in Sweden

“Shaping Melanoma Care: Insights for UV Safety Month”

🌟 Exciting Insights! Learn how system dynamics modelling shapes the future of cutaneous malignant melanoma care during UV Safety Month. Discover key strategies for better healthcare planning and patient outcomes. #SyenzaNews #UVSafetyMonth #HealthcarePlanning #MelanomaCare #PreventiveInterventions 🏥

skin cancer primary prevention

Enhancing Skin Cancer Prevention in a Primary Care Setting

🌞 Discover the latest strategies in skin cancer primary prevention! From innovative risk assessment tools to new technologies, learn how primary care can play a pivotal role in reducing skin cancer rates.
🩺👩‍⚕️👨‍⚕️ #SyenzaNews #Healthcare #SkinCancerPrevention #PrimaryCare #Innovation

Valvular heart disease in Saudi Arabia

Addressing Valvular Heart Disease in Saudi Arabia

#SyenzaNews 🚀 Valvular heart disease (VHD) is a growing concern in Saudi Arabia, especially among the ageing population.
Discover the current challenges and actionable recommendations to enhance VHD care.

Let’s work together to improve awareness, detection, and treatment! #Healthcare #Cardiology #SaudiArabia #HealthyAging 🌟

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.